To examine whether cancer immunotherapy effectiveness varies between female and male patients with advanced melanoma treated with either nivolumab plus ipilimumab combination therapy or anti–programmed cell death protein 1 (PD-1) therapy (namely, pembrolizumab or nivolumab). Here, PDCD1 is linked to cancer.